FDA Approved: TRYVIO — Original Application (Idorsia Pharmaceuticals Ltd)

View source ↗

Summary

FDA approves TRYVIO (aprocitentan) from Idorsia in an Original Application (NDA217686) for the treatment of pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• TRYVIO (APROCITENTAN)

Snippet

ORIG AP for TRYVIO (APROCITENTAN)